Profile data is unavailable for this security.
About the company
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
- Revenue in USD (TTM)18.36m
- Net income in USD-163.41m
- Incorporated2014
- Employees449.00
- LocationAdaptimmune Therapeutics PLC60 Jubilee Avenue, Milton ParkABINGDON OX14 4RXUnited KingdomGBR
- Phone+44 123 543 0000
- Websitehttps://www.adaptimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 268.89m | 54.00 | -- | 2.41 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 277.31m | 140.00 | -- | 35.86 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Medifast Inc | 897.81m | 67.76m | 281.52m | 634.00 | 4.15 | 1.33 | 3.47 | 0.3136 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 285.10m | 123.00 | -- | 10.19 | -- | 7.44 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Nature's Sunshine Products Inc | 447.68m | 16.54m | 286.94m | 814.00 | 18.07 | 1.87 | 9.62 | 0.641 | 0.8479 | 0.8479 | 22.96 | 8.20 | 1.86 | 1.91 | 44.39 | 549,974.20 | 7.33 | 6.57 | 10.66 | 9.41 | 72.19 | 72.69 | 3.94 | 3.74 | 1.42 | -- | 0.013 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 288.79m | 449.00 | -- | 11.84 | -- | 15.73 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| CorMedix Inc | 0.00 | -50.24m | 289.75m | 82.00 | -- | 4.99 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 289.90m | 335.00 | -- | 3.42 | -- | 3.51 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 296.63m | 534.00 | -- | -- | -- | 1.25 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 297.39m | 203.00 | -- | 0.5467 | -- | 1.67 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 298.14m | 59.00 | -- | 2.51 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 298.69m | 1.60k | -- | 0.4499 | -- | 0.252 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 299.45m | 50.00 | -- | 2.24 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| XOMA Corp | 5.81m | -45.09m | 300.16m | 13.00 | -- | 3.65 | -- | 51.65 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Q32 Bio Inc | 354.00k | -83.09m | 304.52m | 39.00 | -- | 6.24 | -- | 860.24 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Data as of Jun 04 2024. Currency figures normalised to Adaptimmune Therapeutics PLC's reporting currency: US Dollar USD
48.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Mar 2024 | 38.97m | 15.25% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 27.40m | 10.72% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 15.87m | 6.21% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 10.79m | 4.22% |
| Long Focus Capital Management LLCas of 31 Mar 2024 | 10.68m | 4.18% |
| PFM Health Sciences LPas of 31 Mar 2024 | 10.42m | 4.08% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 4.66m | 1.82% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 2.43m | 0.95% |
| Tang Capital Management LLCas of 31 Mar 2024 | 1.44m | 0.57% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.39m | 0.55% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
